Morningstar

CSL Ltd CSL

Morningstar Rating
Unlock
Stock XASX Rating as of
A$197.10 +0.32 (0.16%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Price vs Fair Value

View History
CSL is trading within a range we consider fairly valued.
Price
A$197.10
Fair Value
#?P
Uncertainty
LOCK|KZ
1-Star Price
LOCK|L.QFt
5-Star Price
&L^
Economic Moat
LOCK|yJL#R
Capital Allocation
LOCK|&$Yg<?S

Bulls Say, Bears Say

Bulls

CSL is investing in plasma yield initiatives, leaving it well positioned to take advantage of growth opportunities in the key immunoglobulins market.

Bears

Areas of the plasma industry could be replaced by newer therapies, which would leave CSL overinvested in plasma collection and fractionation capacity that will be hard to repurpose.

Show More

News

View All

Trading Information

Previous Close Price
A$196.78
Day Range
A$195.15–199.00
52-Week Range
A$90.00–199.00
Bid/Ask
A$196.00 / A$197.10
Shares Outstanding
479.88M
Market Cap
A$94.59B
Volume/Avg
1M / 1M

Key Statistics

Price/Earnings (Normalized)
22.58
Price/Sales
4.10
Dividend Yield (Trailing)
2.06%
Dividend Yield (Forward)
2.06%
Dividend Payment Schedule
Apr, Oct
Total Yield
3.14%

Company Profile

CSL is one of the largest global biotech companies and has three main segments. CSL Behring uses either plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D record, and its product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and one-fourth in Europe.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Core
Total Number of Employees
30,000
Website
https://www.csl.com

Competitors

Valuation

View More
Metric
CSL
4502
SNY
Price/Earnings (Normalized)
 22.5853.0711.90
Price/Book Value
 4.391.321.39
Price/Sales
 4.102.161.78
Price/Cash Flow
 18.3212.067.36
Price/Earnings
CSL
4502
SNY

Financial Strength

Metric
CSL
4502
SNY
Quick Ratio
 0.880.540.49
Current Ratio
 2.211.140.99
Interest Coverage
 −8.460.078.05
Quick Ratio
CSL
4502
SNY

Profitability

Metric
CSL
4502
SNY
Return on Assets (Normalized)
 8.38%5.53%7.96%
Return on Equity (Normalized)
 17.61%11.34%14.96%
Return on Invested Capital (Normalized)
 11.10%7.74%11.28%
Return on Assets
CSL
4502
SNY

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|P#DVZtLOCK|q^>S$132B
 Regeneron Pharmaceuticals Inc
REGN
LOCK|@cV!H?LOCK|yZCGB$84B
 Moderna Inc
MRNA
LOCK|G#j!h>vLOCK|PDv$83B
 argenx SE ADR
ARGX
LOCK|@>VgcrLOCK|mS$55B
 BeOne Medicines Ltd ADR
ONC
LOCK|%$pmNk!LOCK|@Z$42B
 Alnylam Pharmaceuticals Inc
ALNY
LOCK|fn>QcgLOCK|!MS%$30B
 Royalty Pharma PLC Class A
RPRX
LOCK|?<%&q^K@LOCK|^JTp$29B
 Incyte Corp
INCY
LOCK|MZXSDKLOCK|Cg$24B
 BioNTech SE ADR
BNTX
LOCK|Tg$WRhLOCK|Z!x$22B
 BridgeBio Pharma Inc
BBIO
LOCK|Z^g^!B>LOCK|Q?$14B

Sponsor Center